



**10<sup>th</sup> Translational Research Conference**  
**Myelodysplastic Syndromes, Overlap MDS/MPN, Disorders and Clonal Hematopoiesis**

October 16-18, 2026 - Malahide (Dublin), Ireland  
Chairpersons: P. Fenaux, M. Sekeres, K. Götze

**Friday, October 16<sup>th</sup>, 2026**

**08:30–08:40 Welcome**

**SESSION I – Myelodysplastic Syndromes and the march of clonal hematopoiesis**

**Chair: Katharina Götze (Munich)**

|             |                                                              |                          |
|-------------|--------------------------------------------------------------|--------------------------|
| 08:40-08:45 | Introduction                                                 | Katharina Götze (Munich) |
| 08:45-09:00 | The inexorable march of clonal evolution                     | Klaus Metzeler (Leipzig) |
| 09:00-09:05 | <i>Discussion</i>                                            |                          |
| 09:05-09:20 | How do we define myelodysplastic syndromes progression?      | Amy DeZern (Baltimore)   |
| 09:20-09:25 | <i>Discussion</i>                                            |                          |
| 09:25-09:40 | Where's the line between CCUS and myelodysplastic syndromes? | Katharina Götze (Munich) |
| 09:40-09:45 | <i>Discussion</i>                                            |                          |
| 09:45-09:52 | <i>Selected brief oral communication</i>                     | Speaker                  |
| 09:52-09:55 | <i>Discussion</i>                                            |                          |
| 09:55-10:25 | <i>Panel discussion</i>                                      |                          |

**10:25-10:55 Coffee Break**

**SESSION II – The VEXAS nexus**

**Chair: David Beck (New York)**

|             |                                                            |                          |
|-------------|------------------------------------------------------------|--------------------------|
| 10:55-11:00 | Introduction                                               | David Beck (New York)    |
| 11:00-11:15 | Genobiology of VEXAS                                       | Olivier Kosmider (Paris) |
| 11:15-11:20 | <i>Discussion</i>                                          |                          |
| 11:20-11:35 | the Many faces of VEXAS: clinical manifestations           | David Beck (New York)    |
| 11:35-11:40 | <i>Discussion</i>                                          |                          |
| 11:40-11:55 | Treating the immune consequences and core problem of Vexas | Emma Groarke (Bethesda)  |
| 11:55-12:00 | <i>Discussion</i>                                          |                          |

Draft\_31/07/2025

12:00-12:15 Can we modify the natural history of VEXAS? Thibault Comont (Toulouse)

12:15-12:20 *Discussion*

12:20-12:27 *Selected brief oral communication*

12:27-12:30 *Discussion*

Speaker

12:30-13:00 *Panel discussion*

**13:00-14:40 Lunch**

**13:30-14:30 Possible slot for a satellite symposium**

### **SESSION III – Not another session on myelodysplastic syndromes classification and risk!**

**Chair: Pierre Fenaux (Paris)**

14:40-14:45 Introduction Pierre Fenaux (Paris)

14:45-15:00 the ICC and WHO classification: a marriage made in heaven Robert Hasserjian (Boston)

15:00-15:05 *Discussion*

15:05-15:20 Where the IPSSM succeeds and where it falls short

Aristoteles Giagounidis (Düsseldorf)

15:20-15:25 *Discussion*

15:25-15:40 How artificial intelligence will transform classification and risk in myelodysplastic syndromes

Matteo Giovanni Della Porta (Milan)

15:40-15:45 *Discussion*

15:45-15:52 *Selected brief oral communication*

Speaker

15:52-15:55 *Discussion*

15:55-16:25 *Panel discussion*

**16:25-16:55 Coffee break**

### **SESSION IV – Special Genetic Populations**

**Chair: Michaela Fontenay (Paris)**

16:55-17:00 Introduction Michaela Fontenay (Paris)

17:00-17:15 The fault, dear Brutus, lies within ourselves: Germline predisposition

Marie Sebert (Paris)

17:15-17:20 *Discussion*

17:20-17:35 The Science of TP53

Francesc Solé (Barcelona)

17:35-17:40 *Discussion*

17:40-17:55 Splicing factor mutations

Michaela Fontenay (Paris)

17:55-18:00 *Discussion*

18:00-18:15 MDS/MPN overlap and CMML: overlooked in clinical trials....

Raphaël Itzykson (Paris)

18:15-18:20 *Discussion*

|             |                                                                              |         |
|-------------|------------------------------------------------------------------------------|---------|
| 18:20-18:27 | <i>Selected brief oral communication</i>                                     | Speaker |
| 18:27-18:30 | <i>Discussion</i>                                                            |         |
| 18:30-19:00 | <i>Panel discussion and/or controversial debates</i>                         |         |
| 19:10       | <b>Mentored Poster Walks and Welcome Get Together stand up buffet dinner</b> |         |

## Saturday, October 17<sup>th</sup>, 2026

### 08:00-09:00 2 Simultaneous Meet the Expert sessions (non-clinical)

1. NGS : Methods, interpretation of what is pathogenic and what is not, etc Klaus Metzeler (Leipzig)
2. Quality of Life PROs Fabio Efficace (Rome)

### 09:00-10:00 Possible slot for a satellite symposium

### 10:00-10:30 Coffee break

### SESSION V – Looking at myelodysplastic syndromes with a Crystal Ball

Chair: Valeria Santini (Florence)

|             |                                                                             |                            |
|-------------|-----------------------------------------------------------------------------|----------------------------|
| 10:30-10:35 | Introduction                                                                | Valeria Santini (Florence) |
| 10:35-10:50 | Numbers and Nuances of myelodysplastic syndromes epidemiology               | Nancy Gillis (Tampa)       |
| 10:50-10:55 | <i>Discussion</i>                                                           |                            |
| 10:55-11:10 | Predicting response in lower- and higher-risk myelodysplastic syndromes     | Valeria Santini (Florence) |
| 11:10-11:15 | <i>Discussion</i>                                                           |                            |
| 11:15-11:30 | Asking the patient about benefits of treatment in myelodysplastic syndromes | Fabio Efficace (Rome)      |
| 11:30-11:35 | <i>Discussion</i>                                                           |                            |
| 11:35-11:42 | <i>Selected brief oral communication</i>                                    | Speaker                    |
| 11:42-11:45 | <i>Discussion</i>                                                           |                            |
| 11:45-12:15 | <i>Panel discussion</i>                                                     |                            |
| 12:15-13:55 | <b>Lunch</b>                                                                |                            |

### 12:45-13:45 Possible slot for a satellite symposium

### SESSION VI – Treating Lower-risk myelodysplastic syndromes

Chair: Mikkael Sekeres (Miami)

|             |              |                         |
|-------------|--------------|-------------------------|
| 13:55-14:00 | Introduction | Mikkael Sekeres (Miami) |
|-------------|--------------|-------------------------|

|                    |                                                                                                                        |                                    |
|--------------------|------------------------------------------------------------------------------------------------------------------------|------------------------------------|
| 14:00-14:15        | Upfront therapy for anemia in lower-risk myelodysplastic syndromes:<br>the case for ESAs and the case for luspatercept | Eva Hellstrom-Lindberg (Stockholm) |
| 14:15-14:20        | <i>Discussion</i>                                                                                                      |                                    |
| 14:20-14:35        | Second-line therapies for lower-risk myelodysplastic syndromes                                                         | Sophie Park (Grenoble)             |
| 14:35-14:40        | <i>Discussion</i>                                                                                                      |                                    |
| 14:40-14:55        | To all regulatory bodies: These should be the response criteria for lower-risk myelodysplastic syndromes!              | Mikael Sekeres (Miami)             |
| 14:55-15:00        | <i>Discussion</i>                                                                                                      |                                    |
| 15:00-15:07        | <i>Selected brief oral communication</i>                                                                               | Speaker                            |
| 15:07-15:10        | <i>Discussion</i>                                                                                                      |                                    |
| 15:10-15:40        | <i>Panel discussion</i>                                                                                                |                                    |
| <b>15:40-16:10</b> | <b><i>Coffee break</i></b>                                                                                             |                                    |

## SESSION VII – Treating Higher-risk myelodysplastic syndromes

Chair: Amer Zeidan (New Haven)

|                    |                                                                                                            |                                   |
|--------------------|------------------------------------------------------------------------------------------------------------|-----------------------------------|
| 16:10-16:15        | Introduction                                                                                               | Amer Zeidan (New Haven)           |
| 16:15-16:30        | Epigenetic dysregulation in myelodysplastic syndromes                                                      | Maria Figueroa (Miami)            |
| 16:30-16:35        | <i>Discussion</i>                                                                                          |                                   |
| 16:35-16:50        | The case for first-line therapies other than HMAs in higher-risk myelodysplastic syndromes                 | Lionel Adès (Paris)               |
| 16:50-16:55        | <i>Discussion</i>                                                                                          |                                   |
| 16:55-17:10        | Combination therapies for higher-risk myelodysplastic syndromes:<br>Not quite dead yet                     | Guillermo Garcia-Manero (Houston) |
| 17:10-17:15        | <i>Discussion</i>                                                                                          |                                   |
| 17:15-17:30        | To all regulatory bodies: These should be the response criteria for higher-risk myelodysplastic syndromes! | Amer Zeidan (New Haven)           |
| 17:30-17:35        | <i>Discussion</i>                                                                                          |                                   |
| 17:35- 17:42       | <i>Selected brief oral communication</i>                                                                   | Speaker                           |
| 17:42-17:45        | <i>Discussion</i>                                                                                          |                                   |
| 17:45-18:15        | <i>Panel discussion and/or controversial debates</i>                                                       |                                   |
| <b>18:20-19:20</b> | <b>Possible slot for a satellite symposium</b>                                                             |                                   |

## Sunday, October 18<sup>th</sup>, 2026

**07:30-08:30**     **3 Simultaneous Breakfast Meet the Expert Sessions (Clinical)**

Draft\_31/07/2025

1. Treatment of lower-risk myelodysplastic syndromes
2. Treatment of higher-risk myelodysplastic syndromes
3. Treatment of CMML

Valeria Santini (Florence)  
Mikael Sekeres (Miami)  
Raphaël Itzykson (Paris)

## **SESSION VIII – Transplantation**

**Chair(s): TBA**

|                    |                                                                                    |                                |
|--------------------|------------------------------------------------------------------------------------|--------------------------------|
| 08:35-08:40        | Introduction                                                                       | Session Chair                  |
| 08:40-08:55        | Allogeneic transplant for myelodysplastic syndromes: overview of current concepts  | David Valcarcel (Barcelona)    |
| 08:55-09:00        | <i>Discussion</i>                                                                  |                                |
| 09:00-09:15        | Which lower risk myelodysplastic syndromes patients should we transplant and when? | Nicolaus Kröger (Hambourg)     |
| 09:15-09:20        | <i>Discussion</i>                                                                  |                                |
| 09:20-09:35        | Is there a role for CAR-T cell therapy in MDS/AML?                                 | Maria Diez Campelo (Salamanca) |
| 09:35-09:40        | <i>Discussion</i>                                                                  |                                |
| 09:40-09:47        | <i>Selected brief oral communication</i>                                           | Speaker                        |
| 09:47-09:50        | <i>Discussion</i>                                                                  |                                |
| 09:50-10:20        | <i>Panel discussion</i>                                                            |                                |
| <b>10:20-10:50</b> | <b><i>Coffee break</i></b>                                                         |                                |

## **SESSION IX – Academic clinical trials**

**Chair(s): TBA**

|                    |                                                      |                                                               |
|--------------------|------------------------------------------------------|---------------------------------------------------------------|
| 10:50-10:55        | Introduction                                         | Session Chair                                                 |
| 10:55-11:10        | German, EMSCO, Italian                               | Katharina Götze (Munich) &<br>Valeria Santini (Florence)      |
| 11:10-11:15        | <i>Discussion</i>                                    |                                                               |
| 11:15-11:30        | French, Spanish                                      | Pierre Fenaux (Paris) &<br>Maria Diez Campelo (Salamanca)     |
| 11:30-11:35        | <i>Discussion</i>                                    |                                                               |
| 11:35-11:50        | US, others                                           | Guillermo Garcia-Manero (Houston) &<br>Mikael Sekeres (Miami) |
| 11:50-11:55        | <i>Discussion</i>                                    |                                                               |
| 11:55-12:02        | <i>Selected brief oral communication</i>             | Speaker                                                       |
| 12:02-12:05        | <i>Discussion</i>                                    |                                                               |
| 12:05-12:35        | <i>Panel discussion and/or controversial debates</i> |                                                               |
| <b>12:35-12:45</b> | <b><i>Closing Remarks</i></b>                        |                                                               |

**MEETING CLOSURE**